The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.

 
Web www.patentalert.com

< Cholesterol regulating agent

> Human anti-IFN-.gamma. neutralizing antibodies as selective IFN-.gamma. pathway inhibitors

~ 00401